Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

Purpose: Epidermal growth factor receptor (EGFR) is overexpressed in head and neck squamous cell carcinoma (HNSCC) where expression levels correlate with decreased survival. Therapies that block EGFR have shown limited efficacy in clinical trials and primarily when combined with standard therapy. The most common form of mutant EGFR (EGFRvIII) has been described in several cancers, chiefly glioblastoma. The present study was undertaken to determine the incidence of EGFRvIII expression in HNSCC and the biological consequences of EGFRvIII on tumor growth in response to EGFR targeting. Experimental Design: Thirty-three HNSCC tumors were evaluated by immunostaining and reverse transcription-PCR for EGFRvIII expression. A representative HNSCC cell line was stably transfected with an EGFRvIII expression construct. EGFRvIII-expressing cells and vector-transfected controls were compared for growth rates in vitro and in vivo as well as chemotherapy-induced apoptosis and the consequences of EGFR inhibition using the chimeric monoclonal antibody C225/cetuximab/Erbitux. Results: EGFRvIII expression was detected in 42% of HNSCC tumors where EGFRvIII was always found in conjunction with wild-type EGFR. HNSCC cells expressing EGFRvIII showed increased proliferation in vitro and increased tumor volumes in vivo compared with vector-transfected controls. Furthermore, EGFRvIII-transfected HNSCC cells showed decreased apoptosis in response to cisplatin and decreased growth inhibition following treatment with C225 compared with vector-transfected control cells. Conclusions: EGFRvIII is expressed in HNSCC where it contributes to enhanced growth and resistance to targeting wild-type EGFR. The antitumor efficacy of EGFR targeting strategies may be enhanced by the addition of EGFRvIII-specific blockade.

[1]  A Guha,et al.  Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. , 1999, Neurosurgery.

[2]  D. Bigner,et al.  Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. , 1993, Cancer research.

[3]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[4]  J. Grandis,et al.  Retinoic acid normalizes the increased gene transcription rate of TGF–α and EGFR in head and neck cancer cell lines , 1996, Nature Medicine.

[5]  J. Grandis,et al.  Targeting epidermal growth factor receptor in head and neck cancer , 2003 .

[6]  C. A. Thomas,et al.  Molecular cloning. , 1977, Advances in pathobiology.

[7]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[8]  R. Day,et al.  Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .

[9]  C. James,et al.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.

[10]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[11]  W. Cavenee,et al.  Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[13]  H. Zwierzina,et al.  Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. , 2006, European journal of cancer.

[14]  R. Todd,et al.  Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes. , 1999, Cancer research.

[15]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[17]  A. Scott,et al.  Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. , 2001, Cancer research.

[18]  K. Ichimura,et al.  Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas , 2005, Journal of Molecular Medicine.

[19]  K Kian Ang,et al.  Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. , 2004, International journal of radiation oncology, biology, physics.

[20]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[21]  M. Hidalgo,et al.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Suk Woo Nam,et al.  Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck , 2005, Clinical Cancer Research.

[23]  J. Contessa,et al.  Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells , 2002, Oncogene.

[24]  G. Tortora,et al.  Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. , 2003, European journal of cancer.

[25]  J. Welsh,et al.  Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. , 1990, Science.

[26]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[27]  J. Biegel,et al.  Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. , 1995, Cancer research.

[28]  J. Grandis,et al.  Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl‐2 expression and increased susceptibility to cisplatin‐induced apoptosis , 2004, Head & neck.

[29]  A. Friedman,et al.  Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  J. Grandis,et al.  Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. , 1993, Cancer research.

[31]  O. Bogler,et al.  A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.

[32]  D. O’Rourke,et al.  Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters β-Tubulin Isotype Expression* , 2000, The Journal of Biological Chemistry.

[33]  R. B. Montgomery,et al.  Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor* , 1998, The Journal of Biological Chemistry.

[34]  A. Schueler,et al.  Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies , 2005 .

[35]  D. Bigner,et al.  EGF mutant receptor vIII as a molecular target in cancer therapy. , 2001, Endocrine-related cancer.

[36]  A. Godwin,et al.  Expression of constitutively activated EGFRvlll in non‐small cell lung cancer , 2003, Cancer science.

[37]  Kenji Tada,et al.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.

[38]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[39]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Todd,et al.  Expression of a truncated epidermal growth factor receptor in oral squamous cell carcinomas. , 2000, Cancer Letters.

[41]  R. McLendon,et al.  Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.

[42]  J. Wilson,et al.  Cisplatinum and Bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial , 2004, Cancer Chemotherapy and Pharmacology.

[43]  Careen K. Tang,et al.  Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis , 2002, International journal of cancer.

[44]  A. Scott,et al.  Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. , 2001, Cancer research.

[45]  Udo Greiser,et al.  Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. , 2003, Cancer research.

[46]  R. McLendon,et al.  Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.

[47]  B. Zoll,et al.  Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis , 1995, Journal of Neurology.

[48]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[50]  E. Bernhard,et al.  Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin , 2004, Oncogene.

[51]  E. Vokes,et al.  Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  J. Mendelsohn,et al.  Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. , 1983, Molecular biology & medicine.

[53]  J. Grandis,et al.  Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. , 2004, Cancer treatment reviews.

[54]  C. Mamot,et al.  Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.

[55]  G. Riggins,et al.  Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. , 2002, Cancer research.

[56]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[57]  H. Varmus,et al.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. , 1998, Genes & development.

[58]  Vivian Wai Yan Lui,et al.  EGFR-mediated cell cycle regulation. , 2002, Anticancer research.

[59]  P. Humphrey,et al.  Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[60]  M. Meyerson,et al.  Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Allan H Friedman,et al.  Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.